AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 13.8% according to Barclays.
Barclays set a target price of 12,500 GBX for the company, which when compared to the AstraZeneca plc share price of 10,982 GBX at opening today (12/04/2024) indicates a potential upside of 13.8%. Trading has ranged between 9,461 (52 week low) and 12,392 (52 week high) with an average of 1,872,140 shares exchanging hands daily. The market capitalisation at the time of writing is £174,536,430,600.
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.
AstraZeneca plc 13.8% potential upside indicated by Barclays
- Written by: Charlotte Edwards
Latest Company News
The European Commission has approved AstraZeneca’s Trixeo Aerosphere as a maintenance treatment for patients aged 12 and older whose asthma is inadequately controlled with medium-dose ICS/LABA therapy.
The EMA’s CHMP has recommended Klygefa (gefurulimab) for approval as an add-on treatment for adults with AChR antibody-positive generalised myasthenia gravis, based on Phase III PREVAIL trial results.
The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing a 56% reduction in the risk of disease progression or death.
AstraZeneca has reported positive Phase III CROSSING trial results for Tezspire in eosinophilic oesophagitis, with benefits sustained to week 52.
AstraZeneca has priced four tranches of Eurobonds totalling €2.55 billion, with closing expected on 1 September 2026.
Astrazeneca Plc has reported positive SAFFRON Phase III results for Tagrisso and Orpathys, showing improved progression-free and overall survival.
